Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/29674
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRay, Jason C-
dc.contributor.authorCheng, Shuli-
dc.contributor.authorTsan, Kirsten-
dc.contributor.authorHussain, Hassan-
dc.contributor.authorStark, Richard J-
dc.contributor.authorMatharu, Manjit S-
dc.contributor.authorHutton, Elspeth-
dc.date2022-
dc.date.accessioned2022-04-05T04:55:43Z-
dc.date.available2022-04-05T04:55:43Z-
dc.date.issued2022-03-09-
dc.identifier.citationFrontiers in neurology 2022; 13: 842082en
dc.identifier.issn1664-2295
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/29674-
dc.description.abstractThe use of lidocaine (lignocaine) and ketamine infusion in the inpatient treatment of patients with headache disorders is supported by small case series. We undertook a retrospective cohort study in order to assess the efficacy, duration and safety of lidocaine and ketamine infusions. Patients admitted between 01/01/2018 and 31/07/2021 were identified by ICD code and electronic prescription. Efficacy of infusion was determined by reduction in visual analog score (VAS), and patient demographics were collected from review of the hospital electronic medical record. Through the study period, 83 infusions (50 lidocaine, 33 ketamine) were initiated for a headache disorder (77 migraine, three NDPH, two SUNCT, one cluster headache). In migraine, lidocaine infusion achieved a ≥50% reduction in pain in 51.1% over a mean 6.2 days (SD 2.4). Ketamine infusion was associated with a ≥50% reduction in pain in 34.4% over a mean 5.1 days (SD 1.5). Side effects were observed in 32 and 42.4% respectively. Infusion for medication overuse headache (MOH) led to successful withdrawal of analgesia in 61.1% of lidocaine, and 41.7% of ketamine infusions. Lidocaine and ketamine infusions are an efficacious inpatient treatment for headache disorders, however associated with prolonged length-of-stay and possible side-effects.en
dc.language.isoeng
dc.subjectheadache disordersen
dc.subjectketamineen
dc.subjectlidocaineen
dc.subjectmedication overuse headacheen
dc.subjectmigraineen
dc.subjectstatus migrainosusen
dc.titleIntravenous Lidocaine and Ketamine Infusions for Headache Disorders: A Retrospective Cohort Study.en
dc.typeJournal Articleen
dc.identifier.journaltitleFrontiers in neurologyen
dc.identifier.affiliationNeurologyen
dc.identifier.affiliationSchool of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia..en
dc.identifier.affiliationDepartment of Neurology, Alfred Hospital, Melbourne, VIC, Australia..en
dc.identifier.affiliationDepartment of Neuroscience, Monash University, Melbourne, VIC, Australia..en
dc.identifier.affiliationHeadache and Facial Pain Group, University College London Queen Square Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, United Kingdom..en
dc.identifier.affiliationHeadache and Facial Pain Group, University College London, London, United Kingdom..en
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/35356451/en
dc.identifier.doi10.3389/fneur.2022.842082en
dc.type.contentTexten
dc.identifier.orcid0000-0003-4833-5507en
dc.identifier.pubmedid35356451
local.name.researcherRay, Jason C
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
crisitem.author.deptNeurology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

108
checked on Dec 24, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.